In recent news, the European Commission passed an extension (EU Regulation 2023/607) to the transition deadline for...

Explore our library of blogs, short videos, virtual event recordings and training topics
In recent news, the European Commission passed an extension (EU Regulation 2023/607) to the transition deadline for...
Update on the EU EUDAMED Timeline On 6 July 2022, the European Commission (EC) updated the publicly posted timeline...
In the latest edition of 'Coffee Talk', Reed Tech UDI experts, Gary Saner (Sr. Manager of Information Solutions) and...
Pharma manufacturers and authorized distributors need to submit distribution reports electronically in an eXtensible Markup Language (XML) format to comply with the guidance entitled Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act. This guidance fulfills the Drug Sample Transparency Act specification of ACA Section 6004. These amounts must be reported each year by April 1st for the previous calendar year.
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) was signed into law on December 29, 2022. This law, which provides a major overhaul of existing cosmetic regulations, requires the Food and Drug Administration (FDA) to create Good Manufacturing Practices for all cosmetics manufacturers. The law states that these established practices must include mandatory reporting of serious adverse health events caused by cosmetic products and mandatory testing of asbestos levels. This law will also include updates to cosmetic listing requirements.
This is a quick summary of the December 14, 2022 Emergo Webinar presented by Kenji Yashiro on the topic: Medical...
With the US Class I UDI enforcement quickly approaching, you may be wondering “what about older inventory”? In 2013,...
Reed Tech Life Sciences representative Patti Shragher attended The Vision Expo West 2022 conference, on...
During early-stage drug concept and discovery, Pharmaceutical companies will find it necessary to research the market...